KANAGAWA, Japan & LITTLE ROCK, Ark.– Kuria Therapeutics, Inc., a US pharmaceutical company developing novel therapeutics for ophthalmic and dermal diseases, and SCOHIA PHARMA, Inc, a Japanese biotech company dedicated to developing medicines for lifestyle-related diseases with high unmet needs, today announced that the companies have entered into a licensing agreement under which Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of SCOHIA’s internally discovered novel Nrf2 activators, for prevention and/or treatment of eye and skin diseases. The initial topical ophthalmic solution product candidate containing SCO-116 has been designated by Kuria as KTX-101.
Under the terms of the agreement, SCOHIA PHARMA will receive an upfront payment as well as additional milestone payments of up to USD 67 million if certain global regulatory, development, and sales milestones are achieved. SCOHIA PHARMA is also eligible to receive tiered royalties as a percentage of net sales. Kuria will be responsible for worldwide development, manufacturing, and commercialization in the selected indications with the oversight of a Joint Steering Committee comprised of individuals from both companies, while SCOHIA PHARMA retains the worldwide rights for SCO-116 for local delivery other than for eye and skin diseases as well as the systemic formulation.
The Nrf2 pathway is widely recognized as the master regulator of the antioxidant response, and plays a key role in cellular defense against external insults and pathogens, as well as the regulation of the inflammatory response. Activation of Nrf2 may be beneficial in a wide array of diseases of the eye and skin involving oxidative stress and inflammation, and has been demonstrated to be beneficial in preclinical models of multiple eye diseases, including ocular surface disease, corneal dystrophies, glaucoma, macular degeneration, and diabetic eye disease. The R&D team at SCOHIA has discovered SCO-116, a novel, potent, selective activator of the Nrf2 pathway with demonstrated activity in multiple animal disease models. The licensing agreement announced today will allow Kuria to develop locally delivered formulations of SCO-116 in ophthalmic and dermal disease.
“We are excited about the opportunity to initiate our development efforts with the Nrf2 activator discovered by SCOHIA PHARMA,” stated Dr. Keith Ward, President and Chief Executive Officer of Kuria Therapeutics. “The R&D team at SCOHIA executed a world-class discovery effort to identify and characterize a series of novel Nrf2 activators, and we are honored to partner with such a high-quality team to explore the therapeutic potential of SCO-116 in multiple ophthalmic and dermal diseases.”
“With their deep knowledge and experience in ophthalmology and the development of Nrf2 activators, we are confident that Kuria will be an excellent partner to accelerate development of SCO-116 and deliver it to patients with skin and eye diseases awaiting novel therapies,” added Masanori Watanabe, President, CEO, and CSO of SCOHIA PHARMA. “Kuria’s development of locally delivered therapy directly to affected tissue will complement our efforts to develop SCO-116 systemically in diseases of the liver, kidney, and other organs and add significant value.”
